Novel Coronavirus from China: Nuisance Cold Virus or the next SARS?

Keith M. Ramsey, M.D. Clinical Professor of Medicine The Brody School of Medicine at ECU

Medical Director of Infection Control Vidant Medical Center

OBJECTIVES

- 1. To be able to list the most common Coronavirus strains-vs-Novel Coronavirus
- 2. To be able to list the methods of diagnosis for a candidate case
- 3. To be able to place a candidate patient on the proper isolation precautions

Happy New Year!

- On December 31, 2019, the World Health Organization(WHO) was alerted to several cases of pneumonia in Wuhan City, Hubei Province of China, and the virus detected did not match any other known virus.
- On January 7th, Chinese authorities confirmed that they had identified a new virus, a coronavirus, and in the family of viruses that include the common cold, SARS, MERS, and is named "2019-nCoV"
- On January 14, the sequence of 2019-nCoV was published online, and we read of 14 healthcare workers infected in China

2019-n-CoV Global Map:* ? Pandemic



*As of 2-10-2020 https://www.cdc.gov/coronavirus/2019-ncov/locations-confirmed-cases.html#map

WUHAN CORONAVIRUS OUTBREAK*

CORONAVIRUS CASES 43,143


DEATHS 1018

RECOVERED:

4336

* As of 2-11-2020; Worldometer https://www.worldometers.info/coronavirus/

The Triangle has its Eye on 2019-n-CoV



2019-nCoV in US*



2019 Novel Coronavirus (2019-nCoV) in the U.S.

Updated February 10, 2020

CDC is closely monitoring an outbreak of respiratory illness caused by a novel (new) coronavirus named <u>2019-nCoV</u>. The outbreak first started in Wuhan, China, but cases have been identified in a growing number of other <u>international locations</u>, including the United States. This page will be updated regularly on Mondays, Wednesdays, and Fridays.

People Under Investigation (PUI) in the United States*+

Positive	12
Negative	318
Pending ⁶	68
Total	398

*Cumulative since January 21, 2020.

⁺Numbers closed out at 7 p.m. the night before reporting.

^sIncludes specimens received and awaiting testing, as well as specimens in route to CDC.

Number of states and territories with PUI: 37

*as of 2-11-2020 https://www.cdc.gov/coronavirus/2019-ncov/cases-in-us.html

What is going to happen with 2019-nCoV?

- What is it's infectivity?
- What is the incubation period?
- What is the source of the 2019-nCoV?
- What is the mortality rate?
- What measures can we take to prevent it?
- Will it result in a pandemic?
- Will we have a vaccine?

PATIENT CASE

A male patient was admitted February 22, 2003 to a Hong Kong hospital in respiratory distress.

He had symptoms of a respiratory tract infection since February 15 in Guangdong Province, China. He died the following day.

PATIENT CASE

Differential Diagnosis


- Influenza A, B
- "Avian Flu"
- Adenovirus
- Hantavirus
- Parainfluenza
- ARDS

SARS UPDATE

Search for Pathogen


 Lung Pathology
 Lack of isolation of Influenza A or B, Parainfluenza, Adenovirus
 Virus isolation on Vero 6 cells with classic "rounding up"

Syncytial Giant Cells



Kaye M, Druce J, Tran T, et al. EID. 2006; 12 (1): 128-133.

Electron Microscopy



SARS UPDATE

Search for Pathogen

- EM Coronavirus morphology from Canadian and Hanoii cases
 IFA Seroconversions with paired sera No non-ill controls with antibody
- Viral Sequences Coronavirus-like Agent–distinct from known human isolates OC43 and 229E

CORONAVIRUSES

- Isolated in 1960 from a child with a common cold among an outbreak in which Rhinovirus was not isolated*
- 2 human strains known (prior to SARS) 229E and OC43
- Etiology of "winter colds" and uncommon cause of self-limited Pneumonia
- Nosocomial outbreaks among newborns and elderly

*Kendall, EJC, et al. Br Med J. 1962:82-86

Coronavirus Infections in Military Recruits

Three-Year Study with Coronavirus Strains OC43 and 229E¹⁻³

RICHARD P. WENZEL, J. OWEN HENDLEY, JOHN A. DAVIES, and JACK M. GWALTNEY, JR.⁴

TABLE 3

INITIAL SERUM ANTIBODY TITERS AND SEROCONVERSIONS TO CORONAVIRUSES 229E AND OC43 IN MARINE RECRUITS, PARRIS ISLAND, S.C., AND CAMP LEJEUNE, N.C.

OC43		229E			
Initial Serum Titer	No. of Convertors*/ No. of Men	(%)	Initial Serum Titer	No. of Convertors*, No. of Men	
< 10	5/56	(9)	< 4	12/297	(4)
10	19/108	(18)	4	0/29†	
20	15/113	(13)	8	0/25	
40	3/90	(3)**	≥ 16	0/6	
≥ 80	0/17				

*Convertors = men with fourfold antibody rises.

Pneumonia with Coronavirus OC43 in Adult Recruits

Respiratory signs and symptoms

	# with results (%)		
Cough	11/11	100%	
Sore throat	8/11	72%	
$Fever > 102^{\circ}F$	6	54%	
Sputum	6	54%	
Rales	5	45%	
Pneumonia (x-ray)	4	36%	

Wenzel, RP, et.al. Rev Resp Dis 1974;109:621

Survival of human coronaviruses 229E and OC43 in suspension and after drying on surfaces: a possible source of hospital-acquired infections

J. Sizun, M.W. N. Yu and P. J. Talbot

Laboratory of Neuroimmunovirology, Human Health Research Center, INRS-Institut Armand-Frappier, University of Quebec, Laval, Québec, H7V 1B7, Canada

J Hosp Inf. 2000; 46:55-60





Figure 2 Infectivity of HCV-229E (a) and HCV-OC43 (b) after drying for various times on various surfaces: either aluminum (\blacksquare), sterile sponges (\bullet) or latex surgical gloves (\blacktriangle).






* Health-care workers.

⁸/s All guests except G and K stayed on the 9th floor of the hotel. Guest G stayed on the 14th floor, and Guest K stayed on the 11th floor.

[§]Guests L and M (spouses) were not at Hotel M during the same time as index Guest A but were at the hotel during the same times as Guests G, H, and I, who were ill during this period.

FIGURE 2. Number of suspected cases* of severe acute respiratory syndrome, by exposure category and date of illness onset — United States, 2003




*N = 51.
[†]HK = Hong Kong Special Administrative Region, China; GD = Guangdong province, China; Hanoi = Hanoi, Vietnam.

Coronavirus - SARS

- Incubation period from exposure to fever
 2-16 da (Mean 6 da)
- Biphasic Disease
- Radiographic picture consistent with atypical pneumonia
- Virus shed in sputum and feces
- Case Fatality Rate: 4 7% initially; up to 15% among elderly

https://www.cdc.gov/sars/about/faq.html



Copyright © 2005, 2004, 2000, 1995, 1990, 1985, 1979 by Elsevier Inc.

INTERIM CDC GUIDELINES

To Prevent Transmission of SARS

- Personal protective equipment appropriate for standard contact and airborne precautions
- Eye protection
- N95 Respirators
- Hand Hygiene

https://www.cdc.gov/sars/infection/index.html

Treatment of SARS

- Supportive
- ? Ribavirin
- ? Corticosteroids
- Some isolates of a related Coronavirus, Mouse Hepatitis Virus, are susceptible to Interferon alpha in vitro*

*Taguchi F, Siddell, S. Virology 1985;147:41-48

SARS: 10 Yrs Later

- During 2003, 8096 people in 29 countries got SARS, and 774 died
- Only 8 people in the US had SARS, and none of them died
- In six months, the global SARS outbreak cost the world an estimated \$40 billion
- The last known case was in 2004 among laboratory workers

https://www.cdc.gov/dotw/sars/

Back to the Present: Wuhan, China, Novel Coronavirus

- 41 cases initially
- First case date of onset: 12/6/19
- First international notice 12/31/2019
- Associated with Wet Market







NY Times 1-26-2020

2019-n-CoV in Cell Culture and EM

2019-n-CoV CPE


EM in Lung Tissue





Zhu N, et al. NEJM.2020


2019-nCoV Sequenced



0.3

Zhou P, Yang X-L, Wang S-G, et al. bioRxiv. 2020

Outbreak Curve of 2019-nCoV in Wuhan, China





Li, Q, Guan X, Wu P, et al. NEJM.Jan 29, 2020

Clinical Features of Initial 41 Patients infected with 2019-nCoV

- 41 patients admitted in Wuhan: 27/41 (66%) exposed to Huanan seafood market
- Study compared ICU-vsnon-ICU cases for differences by x² test, Fisher's Exact Test, or Mann-Whitney U test
 Huang C, et al. The Lancet. Jan 24, 2020
- Dyspnea and low systolic pressures were the only clinical features with statistical significance:
- 12/13 (92%)-vs- 10/27 (37%) in non-ICU (p = 0.002)
- Lower systolic pressure in ICU cases (p = 0.018)
- Most severe cases had lymphopenia, low Procalcitonin, and all cases had bilateral involvement on Chest X-rays
- ARDS in 12/41; RNAemia in 6/41; 6/41 (15%) died, and 5/13 ICU (32%) died.

Chest Radiographs and CT Scans of Initial Cases of 2019-nCoV





Chan J F-W, et al. The Lancet Jan 24, 2020



• Zhu N, et al. NEJM.2020



Clinical Characteristics of 138 Hospitalized Patients With 2019 Novel Coronavirus–Infected Pneumonia in Wuhan, China



Figure Legend:

Dynamic Profile of Laboratory Parameters in 33 Patients With Novel Coronavirus–Infected Pneumonia (NCIP)Timeline charts illustrate the laboratory parameters in 33 patients with NCIP (5 nonsurvivors and 28 survivors) every other day based on the days after the onset of illness. The solid lines in black show the upper normal limit of each parameter, and the solid line in red shows the lower normal limit of lymphocyte count. JAMA. Published online February 07, 2020. doi:10.1001/jama.2020.1585

 $^{a}P < .05$ for nonsurvivors vs survivors.

Date of download: 2/10/2020

Copyright 2020 American Medical Association. All Rights Reserved.

Case Definition for Novel Coronavirus (2019-nCoV)-infected pneumonia (NCIP) among initial 425 cases

A suspected case is pneumonia that fulfilled all of the following criteria:

- 1. Fever (with or without recorded temperature);
- 2. Radiographic evidence of pneumonia;
- 3. Low or normal WBC or low lymphocyte counts; and
- 4. No reduction in symptoms after antimicrobial therapy for 3 days

OR

has pneumonia and a link to the seafood market in Huanan, or another case of NCIP.


Li, Q, Guan X, Wu P, et al. NEJM. Jan 29, 2020

What is going to happen with 2019-nCoV?

- What is it's infectivity?
- What is the incubation period?
- What is the source of the 2019-nCoV?
- What is the mortality rate?
- What measures can we take to prevent it?
- Will it result in a pandemic?
- Will we have a vaccine?

Basic Reproduction number: R₀

R₀, or R nought, of an infection is the number of cases that one case generates on average over time in an uninfected population.




Values of R₀ of well-known infectious diseases^[1]

	Disease	Transmission	R ₀
	Measles	Airborne	12–18
	Diphtheria	Saliva	6-7
	Smallpox	Airborne droplet	5–7
	Polio	Fecal-oral route	5–7
	Rubella	Airborne droplet	5–7
	Mumps	Airborne droplet	4–7
	Pertussis	Airborne droplet	5.5 ^[2]
	2019-nCoV	Airborne droplet	2.3-5 ^{[3][4]}
5	HIV/AIDS	Sexual contact	2–5
	SARS	Airborne droplet	2–5 ^[5]
	Influenza (1918 pandemic strain)	Airborne droplet	2–3 ^[8]
	Ebola (2014 Ebola outbreak)	Bodily fluids	1.5-2.5 ^[7]


Zhao S, et al. *bioRxiv* 2020:01.23.916395

2019-nCoV Time Events Estimates



Among the initial 425 cases, the mean incubation period was 5.2 days, and the estimated R_0 value is 2.2 (95% CI, 1.4-3.9). Li, Q, Guan X, Wu P, et al. NEJM. Jan 29, 2020


2019-n-CoV Genetics and Possible Source(s)



Dr. Ji and colleagues sequenced the 2019-nCoV and noticed some overlaps with both bat and snake coronaviruses; thus, as snakes hunt bats, they theorize that the spike glycoprotein may have recombined in the bat, and now can infect humans


Ji W, Wang W, Shao X, et al. J Med Virology. 22 Jan 2020

Phylogeny of Human and Bat Coronaviruses



- Ahu N, Zhang D, Wang W, et al. NEJM. Jan 24, 2020
- Wong ACP et al. Global Epidemiology of Bat Coronaviruses. Viruses.2019;11:174

How Bad Will the Coronavirus Outbreak Get?



And age number of people infected by each sick person

Knvul Sheikh, Derek Watkins, Jin Wu and Mika Gröndahl. NY Times, updated Feb. 1, 2020

Comparison of Recent Severe Coronavirus Infections

Coronavirus	Attack Rate (% exposed who become infected)	Case-Fatality Rate	Comment
SARS	50%	10%	Higher in those over 65 yrs, co- morbidities
MERS	8%	20-25%	
2019-nCoV	??	~ 2%*	Higher in those over 65 yrs of age, co- morbidities

* As of 1-28-2020

CDC Travel Health Alert Notice (THAN)

HEALTH ALERT: Travelers from China

There is an outbreak of respiratory illness in China caused by a new coronavirus.

Watch your health for 14 days after leaving China. If you develop a fever, cough, or have difficulty breathing, seek medical care right away.

CALL AHEAD BEFORE GOING TO SEE A DOCTOR OR EMERGENCY ROOM.
 TELL THEM YOUR SYMPTOMS AND THAT YOU WERE IN CHINA.
 GIVE THEM THIS CARD.



https://www.cdc.gov/coronavirus/2019-ncov/travelers/communication-resources.html

If a candidate patient presents from the airport or via referral:

- Patients with a cough should be given a surgical mask to wear upon entry to a healthcare facility or transport
- Obtain a travel history ask about recent travel to China, or exposure to a traveler from China in the last 14 days
- If positive, place the patient into an airborne isolation room, and healthcare workers should wear an N-95 respirator, a face shield, and observe Standard, Contact and Airborne Precautions (ie, gloves and gown)
- Inform Infection Control, who will contact the local Health Department

https://www.cdc.gov/coronavirus/2019-ncov/infection-control.html

Evaluation of Patient Under Investigation (PUI) for 2019-nCoV*

Clinical Features	&	Epidemiologic Risk	
Fever ¹ or signs/symptoms of lower respiratory illness (e.g. cough or shortness of breath)		Any person, including health care workers, who has had close contact ² with a laboratory-confirmed ^{3.4} 2019-nCoV patient within 14 days of symptom onset	
Fever ¹ and signs/symptoms of a lower respiratory illness (e.g., cough or shortness of breath)		A history of travel from Hubei Province , China ^s within 14 days of symptom onset	
Fever ¹ and signs/symptoms of a lower respiratory illness (e.g., cough or shortness of breath) requiring hospitalization ⁴		A history of travel from mainland China⁵ within 14 days of symptom onset	

The criteria are intended to serve as guidance for evaluation. Patients should be evaluated and discussed with public health departments on a case-by-case basis if their clinical presentation or exposure history is equivocal (e.g., uncertain travel or exposure).

https://www.cdc.gov/coronavirus/2019-nCoV/hcp/clinical-criteria.html

* As of 2-2-2020

How do you protect yourself when evaluating or transporting a PUI?

INFECTION ISOLATION PRECAUTIONS

Visitors must report to Nursing Station before entering



Perform hand hygiene before entering and before leaving room

Wear N95 respirator when entering room Visitors see nurse for instruction on proper use.



 $\mathbf{\nabla}$

 \checkmark

Keep door closed

Dietary may not enter No debe entrar el dietista

PRECAUCIONES AMBIENTALES

Los visitantes deben presentarse primero al puesto de enfermeria antes de entrar. Lávese las manos. Póngase mascara N95 confilto al entrar al cuarto. Mantenga la puerta cerrada. No debe entrar el dietista.



isitors must report to Nursing Station before entering.



Perform hand hygiene before entering and before leaving room.



Wear gloves when entering room or cubicle, and/or when touching patient's intact skin, surfaces, or articles in close proximity



Wear gown when entering room or patient cubicle or if clothing will touch patient items

Use patient-dedicated or single-use disposable shared equipment or clean and disinfect shared equipment (BP cuff, thermometers) between patients.

PRECAUCIONES DE CONTACTO

Los visitantes deben presentarse primero al puesto de enfermería antes de entrar. Lávese las manos. Póngase guantes al entrar al cuarto.



SPECIAL AIRBORNE/CONTACT PRECAUTIONS



Visitors, including family, must not enter-report to Nursing Station.

HEALTH CARE WORKERS MUST WEAR

- N95 Respirator (prior fit test required)
- Gloves
 Gown
- Gown
 Protective eyewear
- (you must wear goggles for aerosol-generating procedures)

Reminder: HAND HYGIENE must be performed before entering the room and following removal of PPE and leaving the patient's room.

For questions call the infection Control Professional.

PRECAUCIONES ESPECIALES CONTACTO AÉREO

Visitantes tienen que reportarse en la estación de enfermeras antes de entrar a este cuarto.

Antes De Entrar A Esta Habitación Tiene Que Usar Los Siguientes Artículos De Protección Personal:


- Respirador N95 (es necesaria prueba de ajuste)
- Guantes
 Bata
- Data
 Protección para los ojos
 - (Tiene que ponerse anteojos protectors para procedimientos con aerosol)

Recordatorio: Tiene que lavarse las mano antes de entrar a este cuarto, al quitarse los artículos de protección personal y al salir del cuarto.

Si tiene preguntas liame al Profesional en Control de Infecciones


Algorithm for LRI when SARS-CoV person-toperson transmission is occurring in the world





https://www.cdc.gov/sars/clinical/fig2.html

Viral Respiratory Panel Detections at VMC - Oct 2019-Present




Biofire Respiratory Virus Trends in US: 2019-2020




 Human Rhinovirus/Enterovirus
 Influenza A
 Coronavirus 229E
 Image: Coronavirus 229E
 Image: Coronavirus 100 coronavirus 000 coronaviru

Influenza Season 2019-2020



Vidant Health Hospital Laboratories Weekly Number of Positive Influenza Tests



Adding Names to the Responsibilities

- 1. Surveillance Bill Cleve, Jacci Thomas
- 2. Information Systems IS Karen Bolen
- 3. Education Tracy Langston
- 4. Infection Control and EVS Dr. Ramsey, Kathy Cochran, Jamie Hall; Robert White, EVS
- 5. Communications Brian Wudkwych, Jason Lowery
- 6. Facility Access visitation Julie Oehlert
- 7. Facility Security Gary Askew
- 8. Human Resources, Employee Illness Janet McKinney
- 9. Pharmacy Jim Worden

10. Triage

Dr. Patterson, Dr. Bennett, Christine Walden, Michelle Kent

- Medical Care & Respiratory Dr. Paul Bolin, Dr. Dalzell, Dr. Paul Cook, Dr. Obi, Skip Bangley, Mike Coogan
- 12. Laboratory Dr. John Fallon, Rick Ross, Heather Duncan, Chris Miller
- 13. Transfer Center
 - Dr. Tracy Eskra
- 14. Surge Capacity Brian Floyd, Van Smith, Dr. Paul Camnitz, Kiplan Clemmons, Chris Starbuck
- 15. Bed Capacity and Bed Control Melanie Porter
- 16. Staffing Linda Hofler
- 17. Consumable Supplies and Equipment Ricky Vandiford, Jamie Hall
- 18. Postmortem Care Dr. Karen Kelly
- 19. COOP Linda Hofler, Melanie Porter, Vicki Phillips, Latasha Williams, Susan Fawcett

Final Questions on 2019-nCoV

When might a vaccine become available?

 Dr. Anthony Fauci, Head of the NIAID in Bethesda, says it will take a year What is the new WHO designation for 2019-nCoV?

 COVID-19, for Novel Coronavirus Disease 19

Ramsey's Conclusions

- Vidant and ECU policies and practices toward patients with respiratory symptoms are sound.
- Vigilance and compliance with our practices should reduce if not prevent exposures.
- If we do have cases in the US, with both a lower R₀ value of 2.2 for infectivity and a lower mortality rate of 2% than SARS, they will be less spread and with a lower mortality.
- The 2019-nCoV, will run it's course, and likely decrease if not disappear in the summer months

Novel Coronavirus from China: Nuisance Cold Virus or the next SARS?



Be a virus, see the world.

• Thank you for your attendance!

• Questions?






19 VMC Hospital Functions to Plan

- 1. Surveillance
- 2. Information Systems IS
- 3. Education
- 4. Infection Control
- 5. Communications
- 6. Facility Access visitation
- 7. Facility Security
- 8. Human Resources, Employee Illness
- 9. Pharmacy

- 10. Triage
- 11. Medical Care
- 12. Laboratory
- 13. Transfer Center
- 14. Surge Capacity
- 15. Bed Capacity and Bed Control
- 16. Staffing
- 17. Consumable Supplies and Equipment
- 18. Postmortem Care
- 19. COOP

A Novel Coronavirus in Patients with SARS



Clinical Features of the Canadian Patients with SARS at Presentation

Variable	# with result	s (%)
 Investigations Aspartate aminotransferase (>1.5 x upper limit of normal) 	■ 7/9	(78)
 Alanine aminotransferase (>1.5 x upper limit of normal) 	■ 5/9	(56)
	■ 5/9	(56)

Creatine kinase (above upper limit of normal)

Classification of Coronaviruses

- Group I: Hu Cov 229E
- Group II: Hu CoV Oc43
- Group III: SARS CoV
- CVLPs
- Toroviruses

Clinical Features of the Canadian Patients with SARS at Presentation

Variable Symptoms


- Fever
- Nonproductive cough
- Dyspnea
- Malaise
- Diarrhea
- Chest pain
- Headache
- Sore throat
- Myalgias
- Vomiting

with results (%)

- **10 / 10 (100)**
- 10 / 10 (100)
- 8 / 10 (80)
- **7 / 20 (70)**
- **5 / 10 (50)**
- **3 / 10 (30)**
- **3 / 10 (30)**
- 3 / 10 (30)
- 2 / 10 (20)
- 1 / 10 (10)


Open Air Markets in Wuhan and other cities in China





NY Times 1-26-2020

Epidemiological Work-up of Unidentifed Pneumonia in China







Figure 2: Timeline of 2019-nCoV cases after onset of illness

Huang C, et al. The Lancet. Jan 24, 2020



Clinical Features of the Canadian Patients with SARS at Presentation

Variable Investigations

- Infiltrate on chest radiography
- Oxygen saturation on room air < 95%
- Leukopenia (cell count <4 x 10⁹ / liter)
- Lymphopenia (cell count <1.5 x 10⁹ / liter)
- Thrombocytopenia (cell count <130 x 10⁹ / liter)
- Lactate dehydrogenase (above upper limit of normal)

with results (%)

- 9/9 (100)
- **7**/9 (78)
- 2/9 (22)
- 8 / 9 (89)
- 3 / 9 (33)
- **4 / 5 (80)**

Booth CM, Matukas LM. Tomlinson GA, et al. JAMA 2003; 289 (21): 2801-9.

Toronto, Canada / April 15-21, 2003

Characteristics of 11 Health-care workers who had symptoms of SARS following exposure to the index patient during the time of his intubation


HC Worker	Symptom onset date	Suspect or Probable SARS	Occupation
1	April 15	Suspect	Respiratory therapist*
2	April 16	Suspect	ICU Nurse assigned primarily to another pt*
3	April 16	Suspect	ICU Primary Nurse*
4	April 16	Suspect	Respiratory Therapist*
5	April 16	Probable	Ward Physician **
6	April 17	Probable	ICU Physician*
7	April 17	Suspect	ICU Charge Nurse*
8	April 18	Suspect	ICU Physician*
9	April 18	Suspect	Radiology Technician***
10	April 18	Not a case	ICU Nurse assigned primarily to another pt****
11	April 21	Not a case	ICU Physician****

*Provided care before, during, & after intubation in ICU. **Examined pt on ward during morning of April 13. ***Performed Chest radiograph of pt on ward early am April 13 ****Provided care before intubation in ICU


Booth CM, Matukas LM. Tomlinson GA, et al. JAMA 2003; 289 (21): 2801-9.

Families of Bat Coronaviruses

Phylogeny



2019-n-CoV Genetics and Possible Source(s)



Researchers have found that bats carry many coronaviruses; due to replacement of S358 sequence of STING, they have a deceased Interferon response to DNA antigens; thus they may be immunotolerant

Wong ACP et al. Global Epidemiology of Bat Coronaviruses. Viruses.2019;11:174 Xi J, et al. Cell Host and Microbe.2018; 27 (3): 297-301

